HydroPearl Microspheres, HydroPearl Microspheres

K150870 · MicroVention, Inc. · KRD · Dec 21, 2015 · Cardiovascular

Device Facts

• Record ID: K150870
• Device Name: HydroPearl Microspheres, HydroPearl Microspheres
• Applicant: MicroVention, Inc.
• Product Code: KRD · Cardiovascular
• Decision Date: Dec 21, 2015
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.3300
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The HydroPearl Microspheres are intended for embolization of arteriovenous malformations and hypervascular tumors, including uterine fibroids.

Device Story

HydroPearl Microspheres are pre-formed, compressible, calibrated spherical embolic agents composed of biocompatible polyethylene glycol diacrylamide hydrogel. Provided in sterile syringes pre-filled with phosphate buffered saline, they are delivered to treatment sites via catheter under fluoroscopic visualization. Used in clinical settings by physicians, the spheres are mixed with contrast media for radiopacity. Upon injection, they provide mechanical occlusion of target vasculature (arteriovenous malformations, hypervascular tumors, uterine fibroids). The device benefits patients by enabling minimally invasive targeted embolization, reducing blood flow to pathological tissues.

Clinical Evidence

No clinical trials were conducted for this submission. Evidence consists of bench testing (mechanical, chemical, catheter compatibility, shelf-life, packaging, sterilization) and animal studies (1, 7, and 30-day) evaluating embolization effectiveness and histopathology (necrosis, inflammation, off-target effects). Biocompatibility testing followed ISO 10993 standards. Published literature on uterine fibroid embolization was provided as supporting information.

Technological Characteristics

Material: Polyethylene glycol diacrylamide hydrogel. Form: Pre-formed, compressible, calibrated spheres (75-1100 μm). Delivery: Catheter-based (0.017"-0.041" ID). Sterilization: Steam (ISO 17665-1). Packaging: Sterile syringe in dispenser tray. MR Safe. Connectivity: None.

Indications for Use

Indicated for embolization of arteriovenous malformations and hypervascular tumors, including uterine fibroids, in patients requiring vascular occlusion.

Regulatory Classification

Identification

A vascular embolization device is an intravascular implant intended to control hemorrhaging due to aneurysms, certain types of tumors (e.g., nephroma, hepatoma, uterine fibroids), and arteriovenous malformations. This does not include cyanoacrylates and other embolic agents, which act by polymerization or precipitation. Embolization devices used in neurovascular applications are also not included in this classification, see § 882.5950 of this chapter.

Special Controls

*Classification.* Class II (special controls.) The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices.” For availability of this guidance document, see § 870.1(e).

Predicate Devices

• Biosphere (Merit Medical) Embosphere Microspheres (K021397)
• Biosphere (Merit Medical) Embosphere Microspheres (K991549)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

December 21, 2015

Microvention, Inc. Naomi Gong Sr. Regulatory Affairs Project Manager 1311 Valencia Ave Tustin, CA 92780

Re: K150870 Trade/Device Name: HydroPearl Microspheres, Regulation Number: 21 CFR 870.3300 Regulation Name: Vascular Embolization Device Regulatory Class: Class II Product Code: KRD, NAJ Dated: December 3, 2015 Received: December 4, 2015

Dear Naomi Gong,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in

{1}------------------------------------------------

the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

**Herbert P. Lerner -S**

for Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K150870

Device Name HydroPearl Microspheres

#### Indications for Use (Describe)

The HydroPearl Microspheres are intended for embolization of arteriovenous malformations and hypervascular tumors, including uterine fibroids.

| Type of Use (Select one or both, as applicable) | |
|-------------------------------------------------|-----------------------------------------------|
| Prescription Ice (Part 21 CER 801 Subnart D) | Over-The-Counter I Isa (21 CER 801 Subnart C) |

## CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(k) Summary

| Trade Name: | HydroPear1TM Microspheres |
|----------------------------------|------------------------------------------------------------------------|
| Generic Name:<br>Classification: | Vascular embolization device<br>Class II, 21 CFR 870.330 (KRD/NAJ) |
| Submitted By: | MicroVention, Inc<br>1311 Valencia Avenue<br>Tustin, California U.S.A. |
| Contact:<br>Date: | Naomi Gong<br>March 30, 2015 |
| | |

## Predicate Devices:

| Number | Description | Clearance Date |
|---------|------------------------------------------------------|-------------------|
| K021397 | Biosphere (Merit Medical) Embosphere<br>Microspheres | November 22, 2002 |
| K991549 | Biosphere (Merit Medical) Embosphere<br>Microspheres | April 26, 2000 |

# Device Description:

The HydroPearl Microspheres are a pre-formed, compressible, precisely calibrated, spherical embolic agent consisting of a biocompatible hydrogel. The HydroPearl Microspheres are offered in a variety of diameters ranging from 75-1100 um and are provided in a sterile syringe pre-filled with microspheres in phosphate buffered saline. The pre-filled syringe is packaged in a sealed sterile dispenser tray. The HydroPearl Microspheres are delivered to the treatment site through a delivery catheter.

## Indications For Use:

The HydroPearl Microspheres are intended for embolization of arteriovenous malformations and hypervascular tumors, including uterine fibroids.

| | Biosphere Medical<br>Embosphere<br>(K021397/K991549) | HydroPearl Microspheres |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| Indications for Use | Intended for embolization of arteriovenous<br>malformations and hypervascular tumors,<br>including uterine fibroids. | Same |
| Microsphere<br>material | Acrylic polymer and impregnated with<br>porcine derived gelatin | Polyethylene glycol diacrylamide |
| Microsphere<br>diameter | 40-1200 μm | 75-1100 μm |
| Microsphere<br>container | Contained in a sterile, 20 ml<br>polycarbonate syringe | Same |
| Microsphere volume<br>per syringe | 1.0 or 2.0 mL<br>Storage media: physiological saline | 2.0 mL<br>Storage media: phosphate buffered saline |
| Delivery method | Delivered to treatment site by catheter under<br>fluoroscopic visualization | Same |
| Radiopacity method | Mixed with contrast media prior to injection | Same |
| Method of supply | Sterile and single use | Same |
| Sterilization<br>Method | Steam | Same |

## Technological Comparison:

{4}------------------------------------------------

# Verification and Test Summary:

| Pre-clinical Testing | | Result |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| Mechanical<br>• Compression<br>• Robustness<br>• Delivery force<br>• Dimensional<br>• Resilience<br>• Time to suspension/time in suspension | Microspheres are capable of:<br>• Temporary deformation with smooth<br>passage through catheter<br>• Syringe to syringe transfer<br>• Delivery through catheter within force<br>specification<br>• Maintains diameter<br>• Suspension (for reference) | Pass |
| Chemical<br>• Residual solvents testing<br>• pH test of solution<br>• Syringe leachables testing | • Meets criteria for residuals<br>• Maintains pH<br>• Syringe does not leach into<br>microsphere/PBS | Meet |
| Magnetic resonance compatibility | Tested to be MR Safe | Pass |
| Catheter compatibility | Microspheres can be delivered through a<br>catheter of 0.017" - 0.041' ID | Pass |
| Compatibility with contrast agents | Microspheres are compatible with contrast<br>agent per IFU | Pass |
| Shelf Life (product/packaging) | After aging conditioning, the<br>microspheres/packaging meet specifications | Pass |
| Animal testing - device compared to predicate<br>device (1 day, 7 day, and 30 day) | To assess embolization effectiveness and<br>histopathological evaluation (necrosis,<br>inflammation, and off-target embolization) | Pass |
| Bicompatibility testing (ISO 10993-1)<br>Cytotoxicity (ISO 10993-5)<br>- MEM elution assay<br>- Agar diffusion assay<br>Sensitization/Irritation (ISO 10993-10)<br>- Guinea pig maximization sensitization<br>- Intracutaneous reactivity<br>Hemocompatibility (ISO 10993-4)<br>- Hemolysis (Direct and Indirect)<br>- Complement Activation<br>- UPTT<br>Systemic toxicity (ISO 10993-11)<br>- Systemic toxicity<br>- Rabbit pyrogen test<br>Implantation (ISO 10993-6)<br>- 2, 13, and 26 wk implantation<br>Genotoxicity (ISO 10993-3)<br>- Ames Test<br>- Chromosomal aberration<br>- Rodent Bone Marrow Micronucleus | Subjected to full battery of biocompatibility<br>testing | Pass |
| Packaging validation | Subjected to ISTA conditions - Packaging<br>testing for adequacy | Pass |
| Sterilization validation | Meets criteria for ISO 17665-1 | Pass |

{5}------------------------------------------------

# Clinical Information:

Other information provided in the 510(k) included published studies/literature on devices for uterine fibroid embolization.

# Conclusions:

The data presented in this submission demonstrates that the HydroPearl Microspheres are as safe, as effective, and perform as well the predicate device, Biosphere (Merit Medical) Embosphere Microspheres.

In summary, the HydroPearl Microspheres described in this substantially equivalent to the predicate device.